Connect your AI

Quest Diagnostics DGX Treasury Stock

Treasury Stock at other companies

Opko HealthOPK

$2.36M+31.9%

Bio-Rad LaboratoriesBIO

$1.01B+30.8%

Idexx LaboratoriesIDXX

$6.93B+20.5%

Other financials

Income statement

Revenue$3.0B+10.2%

Gross profit$1.0B+8.9%

Operating income$459.0M+4.8%

Net income$320.0M+13.5%

EPS (diluted)$2.84+15.0%

Balance sheet

Cash & equivalents$626.0M+96.2%

Total debt$6.4B0.0%

Total equity$7.5B+4.0%

Total assets$16.9B+6.1%

Cash flow

Operating cash flow$597.0M+9.7%

CapEx$138.0M+27.8%

Free cash flow$459.0M+5.3%

Valuation

Market cap$25.15B+34.0%

Enterprise value$30.91B+24.5%

P/E23.7×+3.9×

P/S2.2×+0.4×

Profitability

Gross margin33.1%+0.1pp

Operating margin14.1%+0.1pp

Net margin9.2%+0.2pp

FCF margin11.7%0.0pp

Returns & leverage

Return on equity14.4%+0.7pp

Debt / equity0.8×0.0×

Current ratio1.6×+0.5×

Where this comes from

Reported directly by Quest Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockValue.

The official record: Quest Diagnostics’s 10-Q, filed July 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Quest Diagnostics's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Quest Diagnostics's treasury stock?: Quest Diagnostics (DGX) reported treasury stock of $5.17B in Q2 2026.
How has Quest Diagnostics's treasury stock changed year-over-year?: Quest Diagnostics's treasury stock increased by 8.4% year-over-year, from $4.77B to $5.17B.
What is the long-term trend for Quest Diagnostics's treasury stock?: Over 5 years (2020 to 2025), Quest Diagnostics's treasury stock has grown at a -0.7% compound annual growth rate (CAGR), from $5.37B to $5.18B.
What does treasury stock mean?: Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.